Helen Goergen
-
- Lymphoma Diagnosis and Treatment 36
- Genetic factors in colorectal cancer 3
- Oncology top 5%
- Viral-associated cancers and disorders 7
- Cancer survivorship and care 6
- Neurology top 5%
- CNS Lymphoma Diagnosis and Treatment 9
- Reproductive Medicine top 10%
- Genetics top 10%
-
- Lung Cancer Treatments and Mutations 20
-
- Childhood Cancer Survivors' Quality of Life 8
-
- Acute Lymphoblastic Leukemia research 3
- Co-authors
- Andreas EngertPeter BorchmannMichael FuchsVolker DiehlKarolin BehringerStefanie KreisslBastian von TresckowStephanie Sasse
- Partner nations
- GermanySwitzerlandAustria
In The Last Decade
Helen Goergen
39 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 60
- Pathology and Forensic Medicine 774
- Oncology 524
- Neurology 286
- Reproductive Medicine 85
- Genetics 101
Countries citing papers authored by Helen Goergen
This map shows the geographic impact of Helen Goergen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Goergen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Goergen more than expected).
Fields of papers citing papers by Helen Goergen
This network shows the impact of papers produced by Helen Goergen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Goergen. The network helps show where Helen Goergen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Helen Goergen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 6 | |
| 2 | 2021 | 18 | |
| 3 | 2021 | 13 | |
| 4 | 2020 | 3 | |
| 5 | 2020 | 35 | |
| 6 | 2019 | 2 | |
| 7 | B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG) | 2018 | 0 |
| 8 | 2018 | 33 | |
| 9 | 2018 | 32 | |
| 10 | 2018 | 14 | |
| 11 | PATIENT PREFERENCES - SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT-ASSOCIATED BURDEN AND SIDE EFFECTS | 2016 | 3 |
| 12 | 2016 | 69 | |
| 13 | 2016 | 65 | |
| 14 | 2013 | 27 | |
| 15 | 2013 | 48 | |
| 16 | 2013 | 33 | |
| 17 | 2012 | 60 | |
| 18 | 2012 | 63 | |
| 19 | 2012 | 6 | |
| 20 | 2009 | 9 |
About Helen Goergen
Helen Goergen is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine, having authored 41 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (36 papers), Lung Cancer Treatments and Mutations (20 papers), CNS Lymphoma Diagnosis and Treatment (9 papers), Childhood Cancer Survivors' Quality of Life (8 papers), Viral-associated cancers and disorders (7 papers), Cancer survivorship and care (6 papers), Acute Lymphoblastic Leukemia research (3 papers) and Genetic factors in colorectal cancer (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (774 citations), Oncology (524 citations) and Neurology (286 citations). Helen Goergen has collaborated with scholars based in Germany, Switzerland and Austria. Frequent co-authors include Andreas Engert, Peter Borchmann, Michael Fuchs, Volker Diehl, Karolin Behringer, Stefanie Kreissl, Bastian von Tresckow, Stephanie Sasse, Dennis A. Eichenauer and Julia Meißner. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.